Summit Therapeutics (SMMT) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Summit Therapeutics (SMMT) right now is Ivonescimab FDA review and first approval: The FDA has accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026. Product revenue (TTM) is ~$0 (pre-commercial). If that keeps playing out, the setup is favourable; the risk to it is summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. No one can predict where SMMT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Summit Therapeutics (SMMT) higher?
1. Ivonescimab FDA review and first approval.
The FDA has accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026. This would be the drug's first US approval and the company's first potential commercial product. The decision is a major binary catalyst that could reprice the stock in either direction.
2. Head-to-head data versus Keytruda.
Phase III studies have shown ivonescimab roughly doubling progression-free survival versus Keytruda (pembrolizumab) monotherapy in PD-L1-positive NSCLC in China, and the HARMONi-6 study reported a statistically significant overall survival benefit in squamous NSCLC. If global confirmatory trials such as HARMONi-3 (versus pembrolizumab plus chemotherapy, results expected 2027) and HARMONi-7 replicate that advantage, ivonescimab could challenge the largest oncology franchise in the world. These readouts are the central swing factors for the stock.
3. Pipeline breadth and partnerships.
Summit is expanding ivonescimab beyond first-line NSCLC into colorectal cancer (the AK112-206 Phase II with data at ASCO 2026) and other tumor types, and announced a clinical collaboration with GSK to combine ivonescimab with GSK's B7-H3 antibody drug conjugate. Over 4,000 patients have been treated with ivonescimab in trials globally, plus over 70,000 in the commercial setting in China through Akeso. Broader indications and combinations could widen the eventual market opportunity.
4. Cash runway to fund late-stage trials.
Summit ended the first quarter of 2026 with about $598.7 million in cash, equivalents, and short-term investments, down from roughly $713.4 million at the end of 2025, with net cash used in operations of about $122.3 million in the quarter. That balance funds the large ongoing Phase III program and pre-launch preparation. Because the company is pre-revenue, sustained burn means additional capital raises are possible, which could dilute existing shareholders.
What could weigh on SMMT?
Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts.
Where SMMT trades today
A forecast starts from where the stock actually is. These are SMMT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for SMMT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a SMMT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the SMMT guide and whether SMMT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the SMMT outlook
The bottom line: what is driving Summit Therapeutics (SMMT) is Ivonescimab FDA review and first approval, with product revenue (ttm) at ~$0 (pre-commercial). If that keeps playing out the setup is favourable; the risk is summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. No one can predict the price, so treat any SMMT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around SMMT with Walnut
Use Summit Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Summit Therapeutics (SMMT)?
+
No one can reliably predict where SMMT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Summit Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive SMMT higher?
+
The main growth drivers are Ivonescimab FDA review and first approval; Head-to-head data versus Keytruda; Pipeline breadth and partnerships. Whether they play out is the real question, not a guaranteed path.
What are the risks to SMMT?
+
Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts.
Will SMMT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Summit Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is SMMT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the SMMT "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.